Bachem (BCHMF) to Release Quarterly Earnings on Thursday

Bachem (OTCMKTS:BCHMF) is anticipated to release its results before the market opens on Thursday, March 12th. Analysts expect Bachem to post earnings of $1.11 per share and revenue of $466.9280 million for the quarter.

Bachem Stock Performance

OTCMKTS:BCHMF opened at $76.77 on Tuesday. The stock has a 50-day moving average price of $75.35 and a 200 day moving average price of $68.57. Bachem has a 12-month low of $60.51 and a 12-month high of $82.73.

Analyst Ratings Changes

Several research analysts have weighed in on BCHMF shares. UBS Group upgraded Bachem to a “buy” rating in a research note on Tuesday, December 2nd. Royal Bank Of Canada reiterated an “outperform” rating on shares of Bachem in a research report on Monday, January 26th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Bachem Company Profile

Bachem Holding AG is a Switzerland‐based specialty biochemical company focused on the development, manufacturing and commercialization of peptides and oligonucleotides. Serving pharmaceutical and biotechnology clients as well as academic research institutions, the company offers a broad spectrum of products ranging from custom peptide synthesis for research applications to clinical and commercial‐grade active pharmaceutical ingredients (APIs). Bachem’s expertise extends to process development, scale‐up and GMP‐compliant production, supporting projects in therapeutic areas such as oncology, metabolic disorders and infectious diseases.

Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has grown through strategic investments in production capacity and the acquisition of complementary peptide and oligonucleotide technologies.